Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist immunotherapy resulting in synergic therapeutic e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sathana Dushyanthen, Zhi Ling Teo, Franco Caramia, Peter Savas, Christopher P. Mintoff, Balaji Virassamy, Melissa A. Henderson, Stephen J. Luen, Mariam Mansour, Michael H. Kershaw, Joseph A. Trapani, Paul J. Neeson, Roberto Salgado, Grant A. McArthur, Justin M. Balko, Paul A. Beavis, Phillip K. Darcy, Sherene Loi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/9dca7cf8454b4a3b9462fc4df89bf7de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9dca7cf8454b4a3b9462fc4df89bf7de
record_format	dspace
spelling	oai:doaj.org-article:9dca7cf8454b4a3b9462fc4df89bf7de2021-12-02T14:42:39ZAgonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer10.1038/s41467-017-00728-92041-1723https://doaj.org/article/9dca7cf8454b4a3b9462fc4df89bf7de2017-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-017-00728-9https://doaj.org/toc/2041-1723MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist immunotherapy resulting in synergic therapeutic effects.Sathana DushyanthenZhi Ling TeoFranco CaramiaPeter SavasChristopher P. MintoffBalaji VirassamyMelissa A. HendersonStephen J. LuenMariam MansourMichael H. KershawJoseph A. TrapaniPaul J. NeesonRoberto SalgadoGrant A. McArthurJustin M. BalkoPaul A. BeavisPhillip K. DarcySherene LoiNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-18 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Sathana Dushyanthen Zhi Ling Teo Franco Caramia Peter Savas Christopher P. Mintoff Balaji Virassamy Melissa A. Henderson Stephen J. Luen Mariam Mansour Michael H. Kershaw Joseph A. Trapani Paul J. Neeson Roberto Salgado Grant A. McArthur Justin M. Balko Paul A. Beavis Phillip K. Darcy Sherene Loi Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
description	MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist immunotherapy resulting in synergic therapeutic effects.
format	article
author	Sathana Dushyanthen Zhi Ling Teo Franco Caramia Peter Savas Christopher P. Mintoff Balaji Virassamy Melissa A. Henderson Stephen J. Luen Mariam Mansour Michael H. Kershaw Joseph A. Trapani Paul J. Neeson Roberto Salgado Grant A. McArthur Justin M. Balko Paul A. Beavis Phillip K. Darcy Sherene Loi
author_facet	Sathana Dushyanthen Zhi Ling Teo Franco Caramia Peter Savas Christopher P. Mintoff Balaji Virassamy Melissa A. Henderson Stephen J. Luen Mariam Mansour Michael H. Kershaw Joseph A. Trapani Paul J. Neeson Roberto Salgado Grant A. McArthur Justin M. Balko Paul A. Beavis Phillip K. Darcy Sherene Loi
author_sort	Sathana Dushyanthen
title	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
title_short	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
title_full	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
title_fullStr	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
title_full_unstemmed	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
title_sort	agonist immunotherapy restores t cell function following mek inhibition improving efficacy in breast cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/9dca7cf8454b4a3b9462fc4df89bf7de
work_keys_str_mv	AT sathanadushyanthen agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT zhilingteo agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT francocaramia agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT petersavas agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT christopherpmintoff agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT balajivirassamy agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT melissaahenderson agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT stephenjluen agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT mariammansour agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT michaelhkershaw agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT josephatrapani agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT pauljneeson agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT robertosalgado agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT grantamcarthur agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT justinmbalko agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT paulabeavis agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT phillipkdarcy agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer AT shereneloi agonistimmunotherapyrestorestcellfunctionfollowingmekinhibitionimprovingefficacyinbreastcancer
_version_	1718389647611002880

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

Ejemplares similares